Tempus AI Inc. has announced that six abstracts have been accepted for presentation at the upcoming Society for Immunotherapy of Cancer $(SITC)$ Annual Meeting 2025, scheduled to take place from November 5 to 9 at the Gaylord National Convention Center in National Harbor, Maryland. The company will present new scientific and clinical research findings through six poster presentations. Among the studies to be presented is a novel multi-omic algorithm developed to predict real-world outcomes in patients with rare, advanced solid cancers treated with off-label immune checkpoint inhibitors. Another study will highlight the TargetR computational framework, which integrates pharmacologic, genomic, transcriptomic, and proteomic data to support the discovery and validation of immunotherapy targets. Additionally, Tempus will share exploratory data on its Immune Profile Score $(IPS)$, a DNA- and RNA-based molecular signature, as a potential predictive biomarker for benefit from immune checkpoint inhibitors in patients with microsatellite stable advanced colorectal cancer. The results from these studies will be presented at the SITC Annual Meeting 2025.